Related Experiment Video
Updated: Jan 30, 2026
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
[Gastroenterology and hepatology update 2018]
Kostantinos Gkouvatsos1, Fabrizia D'Angelo1, Stefano Guglielmi1
1Service de gastroentérologie et hépatologie, HUG, 1211 Genève 14.
Insights
Gastroenterology novelties for 2018 include advanced hepatocellular carcinoma monitoring, new treatments for inflammatory bowel diseases like stem cell therapy and tofacitinib for ulcerative colitis, and updated criteria for eosinophilic esophagitis.
Area of Science:
- Gastroenterology
- Hepatology
- Inflammatory Bowel Disease
Background:
- Significant advancements in gastroenterology occurred in 2018.
- Key areas include hepatology, intestinal inflammatory diseases, and esophageal conditions.
Purpose of the Study:
- To summarize major gastroenterology novelties from 2018.
- To provide an update on diagnostic criteria and therapeutic advancements.
Main Methods:
- Review of recent literature and European Commission approvals.
- Focus on advancements in hepatology, inflammatory bowel disease, and esophageal disorders.
Main Results:
- Hepatology: Updates on hepatocellular carcinoma monitoring, Baveno VI criteria for esophageal varices, and cirrhotic cramps management.
- Intestinal Inflammatory Diseases: European Commission approval of stem cell therapy for perianal fistulas and tofacitinib for ulcerative colitis (RCH).
- Esophageal Conditions: Revised diagnostic criteria for eosinophilic esophagitis and a new therapy for primitive biliary cirrhosis.
Conclusions:
- 2018 brought significant therapeutic and diagnostic progress in gastroenterology.
- Novel treatments and updated criteria offer improved patient management strategies.
Abstract:
The purpose of this article is to detail the major gastroenterology novelties for 2018. In the field of hepatology we address the monitoring of hepatocellular carcinoma, the Baveno VI extended criteria for the detection of oesophageal varices and the management of cramps in cirrhotic patients. Concerning intestinal inflammatory diseases, two novel treatments have recently been approved by the European Commission, including injection of stem cells for the treatment of complex perianal fistulas and the JAK inhibitor tofacitinib for the RCH (ulcerative colitis). Finally, we provide an update on the diagnostic criteria for eosinophilic esophagitis and a new therapy that's was recently validated for the treatment of primitive biliary cirrhosis.
